﻿<?xml version="1.0" encoding="utf-8"?><?xml-stylesheet title="XSL_formatting" type="text/xsl" href="cms1260795.aspx"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><language>en-gb</language><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><lastBuildDate>Sat, 17 May 2008 14:51:33 GMT</lastBuildDate><title><![CDATA[aidsmap.com news feed : aidsmap news]]></title><description><![CDATA[aidsmap.com news feed : aidsmap news]]></description><copyright>Copyright NAM 2008</copyright><link>http://www.aidsmap.com</link><atom:link href="http://www.aidsmap.com/cms1260794.aspx" rel="self" type="application/rss+xml" /><image><title><![CDATA[aidsmap.com news feed : aidsmap news]]></title><url>http://www.aidsmap.com/files/file1002517.gif</url><link>http://www.aidsmap.com</link><width>122</width><height>44</height></image><ttl>15</ttl><item><title><![CDATA[Higher LDL cholesterol levels mean better response to anti-HCV treatment in HIV/HCV coinfected patients ]]></title><link>http://www.aidsmap.com/en/news/AB45B27A-C320-41B0-B855-9AE815589693.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">AB45B27A-C320-41B0-B855-9AE815589693</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[HIV/HCV co-infected individuals with higher “bad” LDL cholesterol levels are more likely to respond successfully to anti-hepatitis C treatment than those with lower levels of LDL. While several previous studies had shown higher LDL to predict better treatment response in hepatitis C-monoinfected individuals, this retrospective study – reported in the May 11 issue of AIDS – is the first to show a similar effect in co-infected individuals.
]]></description><category>Hepatitis news</category></item><item><title><![CDATA[Mother-to-child transmission in UK and Ireland has remained below 2% since 1998]]></title><link>http://www.aidsmap.com/en/news/A9C420C3-CA61-42D6-870B-E25C67339E28.asp</link><author>Kelly Morris</author><guid isPermaLink="false">A9C420C3-CA61-42D6-870B-E25C67339E28</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[Since effective strategies have been introduced to reduce the likelihood of mother-to-child transmission (MTCT) of HIV, rates in the UK and Ireland have remained below 2% for nearly ten years due to routine antenatal testing and potent drug regimens, a UK team of researchers report in the May 11th issue of the journal AIDS.
]]></description><category>Mother-to-child transmission news</category><category>UK news</category></item><item><title><![CDATA[Texas jury concludes saliva of HIV-positive man a ‘deadly weapon’, sentenced to 35 yrs jail ]]></title><link>http://www.aidsmap.com/en/news/57E118E4-CC57-4C0E-A200-E7709A67AF1F.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">57E118E4-CC57-4C0E-A200-E7709A67AF1F</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[A 42 year-old HIV-positive man from Texas who spat at a police officer during his 2006 arrest for being drunk and disorderly has been sentenced to 35 years in prison by a Dallas court and must serve at least half of his sentence before being eligible for parole because the jury found that his saliva was a deadly weapon.
]]></description><category>HIV and the law news</category><category>World policy News</category><category>News Features</category></item><item><title><![CDATA[BHIVA: HIV-positive women at increased risk of late pregnancy loss]]></title><link>http://www.aidsmap.com/en/news/A0A95896-B805-4FBA-BCEF-70F42D32BC44.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">A0A95896-B805-4FBA-BCEF-70F42D32BC44</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[HIV-positive women appear to be between two and four times as likely as HIV-negative women to experience late pregnancy loss, according to a retrospective notes review from an east London HIV clinic presented to the 14th  Annual British HIV Association (BHIVA) Conference last month in Belfast.
]]></description><category>Conference news</category><category>Women and HIV news</category></item><item><title><![CDATA[BHIVA: Starting ART earlier has cost implications, public health benefits, says HPA]]></title><link>http://www.aidsmap.com/en/news/0DEB8457-BA84-45E1-BFC1-7F1604298985.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">0DEB8457-BA84-45E1-BFC1-7F1604298985</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[As many as 2500 HIV-positive individuals would become eligible to start antiretroviral therapy (ART) at an annual cost of £25 million once draft guidance recommending ART initiation at 350 cells/mm3 comes into effect, the 14thAnnual British HIV Association (BHIVA) Conference was told last month in Belfast.
]]></description><category>Conference news</category><category>UK news</category><category>Starting treatment news</category></item><item><title><![CDATA[Combining rifampicin with increased doses of lopinavir/ritonavir tablets leads to dangerous increases in liver enzymes]]></title><link>http://www.aidsmap.com/en/news/27AE7BFB-6513-4A43-9B6A-06D4324F355B.asp</link><author>Michael Carter</author><guid isPermaLink="false">27AE7BFB-6513-4A43-9B6A-06D4324F355B</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[Combining increased doses of lopinavir/ritonavir tablets with the anti-tuberculosis drug rifampicin increases the level of key liver enzymes and causes nausea and vomiting, according to a Dutch study published in the May 11th edition of AIDS. 
]]></description><category>Tuberculosis news</category><category>Side-effects news</category><category>Pharmacokinetics news</category></item><item><title><![CDATA[Death rate in Malawi falls by up to 35% due to free HIV treatment]]></title><link>http://www.aidsmap.com/en/news/30FD449B-55C0-43DB-BB66-BC20D1F65D22.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">30FD449B-55C0-43DB-BB66-BC20D1F65D22</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[The death rate among adults in rural Malawi has declined by 10% since the introduction of antiretroviral therapy, and in areas with the highest death rate, it may have declined by up to 35%, according to findings from a London School of Hygiene and Tropical Medicine study published in the May 10th edition of The Lancet.
]]></description><category>Africa news</category><category>Statistics and epidemiology news</category><category>Treatment access news</category></item><item><title><![CDATA[HIV, but not HHV-8, found to increase risk of pulmonary arterial hypertension ]]></title><link>http://www.aidsmap.com/en/news/6C4D233B-52FF-4B27-A06B-0970638D81CF.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">6C4D233B-52FF-4B27-A06B-0970638D81CF</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[Higher pulmonary artery systolic pressure levels – an independent risk factor for pulmonary arterial hypertension – have been found in an HIV-positive study group, as compared to HIV-negative controls. However, no association with human herpesvirus-8 (HHV-8) infection was found. The results were reported in the April 23rd issue of AIDS.
]]></description><category></category></item><item><title><![CDATA[Circumcision and partner reduction should be priorities for HIV prevention, say US researchers]]></title><link>http://www.aidsmap.com/en/news/C823B941-D049-4978-AE79-D9A27EE36E8A.asp</link><author>Michael Carter</author><guid isPermaLink="false">C823B941-D049-4978-AE79-D9A27EE36E8A</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[Investigators in the US are calling for male circumcision and partner reduction to become the focus of prevention efforts in countries with generalised HIV epidemics. In a paper published in the May 9th edition of Science, they argue that although condom use, testing, and treatment of sexually transmitted infections are of value, resource constraints mean that attention should be shifted to the promotion of initiatives known to work: male circumcision and partner reduction.
]]></description><category>Africa news</category><category>Prevention news</category></item><item><title><![CDATA[Does tenofovir increase the risk of efavirenz-associated liver side-effects?]]></title><link>http://www.aidsmap.com/en/news/F459EAFC-6F8F-4AF3-B16D-28CFE436E57A.asp</link><author>Michael Carter</author><guid isPermaLink="false">F459EAFC-6F8F-4AF3-B16D-28CFE436E57A</guid><pubDate>Sat, 17 May 2008 14:51:33 GMT</pubDate><image /><description><![CDATA[Italian investigators have reported three cases which suggest that treatment with tenofovir (Viread) may increase the risk of liver side-effects caused by efavirenz (Sustiva). The reports are published in the May 11th edition of AIDS. 
]]></description><category>Changing treatments news</category><category>Palliative care news</category><category>Hepatitis news</category><category>Side-effects news</category></item></channel></rss>